Operating
Stock-Based Comp
Edwards Lifesciences Stock-Based Comp increased by 15.8% to $45.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.9%, from $40.20M to $45.40M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 9.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
An increase may signal a strategy to preserve cash or align employee interests with shareholders, but it also results in share dilution.
Detailed definition
Stock-based compensation is a non-cash expense where employees and executives are rewarded with equity or stock options...
Peer comparison
High-growth technology firms often have higher stock-based compensation as a percentage of revenue compared to mature industrial firms.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $30.30M | $26.60M | $24.20M | $32.40M | $36.20M | $30.30M | $27.90M | $38.90M | $37.40M | $32.60M | $30.50M | $44.60M | $43.90M | $42.10M | $31.70M | $40.20M | $37.50M | $41.20M | $39.20M | $45.40M |
| QoQ Change | — | -12.2% | -9.0% | +33.9% | +11.7% | -16.3% | -7.9% | +39.4% | -3.9% | -12.8% | -6.4% | +46.2% | -1.6% | -4.1% | -24.7% | +26.8% | -6.7% | +9.9% | -4.9% | +15.8% |
| YoY Change | — | — | — | — | +19.5% | +13.9% | +15.3% | +20.1% | +3.3% | +7.6% | +9.3% | +14.7% | +17.4% | +29.1% | +3.9% | -9.9% | -14.6% | -2.1% | +23.7% | +12.9% |
Range$24.20M – $45.40M
CAGR+8.9%
Avg YoY Growth+10.3%
Median YoY Growth+13.4%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's stock-based comp?
- Edwards Lifesciences (EW) reported stock-based comp of $45.40M in Q1 2026.
- How has Edwards Lifesciences's stock-based comp changed year-over-year?
- Edwards Lifesciences's stock-based comp increased by 12.9% year-over-year, from $40.20M to $45.40M.
- What is the long-term trend for Edwards Lifesciences's stock-based comp?
- Over 4 years (2021 to 2025), Edwards Lifesciences's stock-based comp has grown at a 9.7% compound annual growth rate (CAGR), from $109.30M to $158.10M.
- What does stock-based comp mean?
- The value of company shares given to employees as part of their pay.